Blaze Biosciences ropes in $8.1M for tumor targeting "paint"

Wed, 07/03/2013 - 7:59am
Mass Device

Seattle-based startup Blaze Biosciences raises $8.1M in Series B funding for its tumor-targeting “paint” technology.

healthcare funding

Blaze Biosciences is more than halfway to a targeted $15 million in a Series B round to fund its Tumor Paint, a surgical tool that visually distinguishes solid tumor cells from healthy cells.

Founded in 2010, the Seattle, Wash.-based Blaze Biosciences has roped in about $8.1 million since opening the round in June, and the company has until Aug. 31, 2015, when the round is set to expire, to scrounge up the next $6.9 million.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.